ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 03 May 2017
Last Updated on 01 Jul 2022
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Rivaroxaban 15 mg and 20 mg tablets, and apixaban 2.5 mg and 5 mg tablets for preventing stroke and systemic embolism in patients with NVAF and:
    • CHA2DS2-VASc score of 1 or more for men; and
    • CHA2DS2-VASc score of 2 or more for women.

Rivaroxaban or apixaban should not be used in patients with valvular AF (especially rheumatic mitral stenosis), or patients with prosthetic heart valves.

Subsidy status
Rivaroxaban 15 mg and 20 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

Apixaban 2.5 mg and 5 mg tablets are recommended for reclassification from MAF to the MOH Standard Drug List (SDL). 

SDL subsidy or MAF assistance do not apply to any strengths of dabigatran.

NOACs for preventing stroke and systemic embolism in non-valvular atrial fibrillation (1 Jul 22) PES Anticoagulants to treat and prevent blood clots (Published 1 July 2022)